Journal Mobile Options
Table of Contents
Vol. 115, No. 3-4, 2006
Issue release date: March 2006

3′ End Processing of the Prothrombin mRNA in Thrombophilia

Danckwardt S. · Hartmann K. · Gehring N.H. · Hentze M.W. · Kulozik A.E.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Clinical and genetic studies have led to the discovery of specific genotypes that predispose to thromboembolism in adults and children. The exploration of the underlying pathologies has revealed a broad variety of affected molecular mechanisms. Most recently, the functional analysis of the prothrombin (F2) 20210*A variant revealed increased efficiency of 3′ end processing as a novel genetic mechanism predisposing to human disease. Here, we review the 3′ end processing of the human F2 mRNA and demonstrate how clinically relevant mutations in the F2 gene contribute to thrombophilia by interfering with a tightly balanced architecture of noncanonical 3′ end formation signals.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, Grant R, Israels S, Jardine L, Luke B, Massicotte P, Silva M: Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251–1257.
  2. Weinmann EE, Salzman EW: Deep-vein thrombosis. N Engl J Med 1994;331:1630–1641.
  3. Rosendaal FR: Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1–6.
  4. Richardson MW, Allen GA, Monahan PE: Thrombosis in children: current perspective and distinct challenges. Thromb Haemost 2002;88:900–911.
  5. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999;353:1167–1173.
  6. Nowak-Gottl U, Kosch A, Schlegel N, Salem M, Manco-Johnson M: Thromboembolism in children. Curr Opin Hematol 2002;9:448–453.
  7. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M: Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133:770–776.
  8. Schmidt B, Andrew M: Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96:939–943.
  9. Hundsdoerfer P, Vetter B, Stover B, Bassir C, Scholz T, Grimmer I, Monch E, Ziemer S, Rossi R, Kulozik AE: Homozygous and double heterozygous factor V Leiden and factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. Thromb Haemost 2003;90:628–635.
  10. Kosch A, Kuwertz-Broking E, Heller C, Kurnik K, Schobess R, Nowak-Gottl U: Renal venous thrombosis in neonates: prothrombotic risk factors and long-term follow-up. Blood 2004;104:1356–1360.
  11. Dahlback B: Blood coagulation. Lancet 2000;355:1627–1632.
  12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698–3703.
  13. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L: The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999;93:1–8.
  14. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ: Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997;78:1426–1429.
  15. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, Slifer S, Stone W, Blangero J, Fontcuberta J: Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000;95:2780–2785.
  16. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH: Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706–708.
  17. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE: Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001;28:389–392.
  18. Colgan DF, Manley JL: Mechanism and regulation of mRNA polyadenylation. Genes Dev 1997;11:2755–2766.
  19. Keller W, Minvielle-Sebastia L: A comparison of mammalian and yeast premRNA 3′-end processing. Curr Opin Cell Biol 1997;9:329–336.
  20. Chen F, MacDonald CC, Wilusz J: Cleavage site determinants in the mammalian polyadenylation signal. Nucleic Acids Res 1995;23:2614–2620.
  21. Zhao J, Hyman L, Moore C: Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev 1999;63:405–445.
  22. Higgs DR, Goodbourn SE, Lamb J, Clegg JB, Weatherall DJ, Proudfoot NJ: Alpha-thalassaemia caused by a polyadenylation signal mutation. Nature 1983;306:398–400.
  23. Orkin SH, Cheng TC, Antonarakis SE, Kazazian HH Jr: Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human beta-globin gene. EMBO J 1985;4:453–456.
  24. Jankovic L, Efremov GD, Petkov G, Kattamis C, George E, Yang KG, Stoming TA, Huisman TH: Two novel polyadenylation mutations leading to beta(+)-thalassemia. Br J Haematol 1990;75:122–126.
  25. Rund D, Dowling C, Najjar K, Rachmilewitz E, Kazazian H Jr, Oppenheim A: Two mutations in the (beta)-globin polyadenylylation signal reveal extended transcripts and new RNA polyadenylylation sites. Proc Natl Acad Sci USA 1992;89:4324–4328.
  26. Harteveld CL, Losekoot M, Haak H, Heister GA, Giordano PC, Bernini LF: A novel polyadenylation signal mutation in the alpha 2-globin gene causing alpha thalassaemia. Br J Haematol 1994;87:139–143.
  27. van Solinge WW, Lind B, van Wijk R, Hart HC, Kraaijenhagen RJ: Clinical expression of a rare beta-globin gene mutation co-inherited with haemoglobin E-disease. Eur J Clin Chem Clin Biochem 1996;34:949–954.
  28. Gieselmann V, Polten A, Kreysing J, von Figura K: Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site. Proc Natl Acad Sci USA 1989;86:9436–9440.
  29. Barth ML, Fensom A, Harris A: Prevalence of common mutations in the arylsulphatase A gene in metachromatic leukodystrophy patients diagnosed in Britain. Hum Genet 1993;91:73–77.
  30. Harvey J, Carey W, Morris C: Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype. Hum Mol Genet 1998;7:1215–1219.
  31. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC: Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995;55:3537–3542.
  32. Kleiman FE, Manley JL: Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Science 1999;285:1576–1579.
  33. Takagaki Y, Manley JL: Levels of polyadenylation factor CstF-64 control IgM heavy chain mRNA accumulation and other events associated with B cell differentiation. Mol Cell 1998;2:761–771.
  34. Zhao W, Manley JL: Complex alternative RNA processing generates an unexpected diversity of poly(A) polymerase isoforms. Mol Cell Biol 1996;16:2378–2386.
  35. Colgan DF, Murthy KG, Prives C, Manley JL: Cell-cycle related regulation of poly(A) polymerase by phosphorylation. Nature 1996;384:282–285.
  36. Jacob ST, Terns MP, Maguire KA: Polyadenylate polymerases from normal and cancer cells and their potential role in messenger RNA processing: a review. Cancer Res 1989;49:2827–2833.
  37. Scorilas A: Polyadenylate polymerase (PAP) and 3′ end pre-mRNA processing: function, assays, and association with disease. Crit Rev Clin Lab Sci 2002;39:193–224.
  38. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, Mathieu J, Duranceau A, Codere F, Fardeau M, Rouleau GA: Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998;18:164–167.
  39. Kuwahara M, Kurachi S, Kurachi K: Molecular mechanism of prothrombin G20210A variant: critical new role of exon splicing enhancer in poly (A) tailing. Blood 2004;104:abstract 1944.
  40. Pollak ES, Lam HS, Russell JE: The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood 2002;100:359–362.
  41. Wylenzek M, Geisen C, Stapenhorst L, Wielckens K, Klingler KR: A novel point mutation in the 3′ region of the prothrombin gene at position 20221 in a Lebanese/Syrian family. Thromb Haemost 2001;85:943–944.
  42. Balim Z, Kosova B, Falzon K, Bezzina Wettinger S, Colak Y: Budd-Chiari syndrome in a patient heterozygous for the point mutation C20221T of the prothrombin gene. J Thromb Haemost 2003;1:852–853.
  43. Schrijver I, Lenzi TJ, Jones CD, Lay MJ, Druzin ML, Zehnder JL: Prothrombin gene variants in non-Caucasians with fetal loss and intrauterine growth retardation. J Mol Diagn 2003;5:250–253.
  44. Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, Pforsich M, Frede U, Hentze MW, Kulozik AE: The prothrombin 3′ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 2004;104:428–435.
  45. Lou H, Gagel RF: Alternative RNA processing – its role in regulating expression of calcitonin/calcitonin gene-related peptide. J Endocrinol 1998;156:401–405.
  46. Barabino SM, Keller W: Last but not least: regulated poly(A) tail formation. Cell 1999;99:9–11.
  47. Edwalds-Gilbert G, Veraldi KL, Milcarek C: Alternative poly(A) site selection in complex transcription units: means to an end? Nucleic Acids Res 1997;25:2547–2561.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50